Transdermal selegiline in patients receiving electroconvulsive therapy

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• The concurrent use of monoamine oxidase inhibitors (MAOIs) and electroconvulsive therapy (ECT) is a subject of clinical debate.
• Investigating the safety and efficacy of novel MAOI formulations with ECT is crucial for treatment optimization.

Observation:

• This report details two cases of patients undergoing electroconvulsive therapy (ECT) while receiving transdermal selegiline, a recently approved MAOI for depression.
• Transdermal selegiline was initiated at a low dose prior to the completion of the ECT course.

Findings:

• No complications or adverse events were observed during the concurrent administration of ECT and low-dose, transdermally delivered selegiline.
• The study suggests that this combination treatment is safe for patients with depression.

Implications:

• Beginning low-dose transdermal selegiline before ECT completion presents a viable strategy for preventing relapse in depression.
• This approach may offer a new therapeutic option for managing treatment-resistant depression, enhancing patient outcomes.